ImmuCell (ICCC) Competitors $6.14 -0.04 (-0.65%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$6.30 +0.16 (+2.52%) As of 08/7/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ICCC vs. FENC, BTMD, PRQR, CGC, LRMR, DSGN, LIMN, VTYX, RAPT, and MDWDShould you be buying ImmuCell stock or one of its competitors? The main competitors of ImmuCell include Adherex Technologies (FENC), biote (BTMD), ProQR Therapeutics (PRQR), Canopy Growth (CGC), Larimar Therapeutics (LRMR), Design Therapeutics (DSGN), Liminatus Pharma (LIMN), Ventyx Biosciences (VTYX), Rapt Therapeutics (RAPT), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. ImmuCell vs. Its Competitors Adherex Technologies biote ProQR Therapeutics Canopy Growth Larimar Therapeutics Design Therapeutics Liminatus Pharma Ventyx Biosciences Rapt Therapeutics MediWound ImmuCell (NASDAQ:ICCC) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Is ICCC or FENC more profitable? ImmuCell has a net margin of -1.00% compared to Adherex Technologies' net margin of -45.52%. Adherex Technologies' return on equity of 0.00% beat ImmuCell's return on equity.Company Net Margins Return on Equity Return on Assets ImmuCell-1.00% -1.02% -0.61% Adherex Technologies -45.52%N/A -26.37% Which has more volatility and risk, ICCC or FENC? ImmuCell has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Do analysts rate ICCC or FENC? Adherex Technologies has a consensus target price of $13.00, suggesting a potential upside of 61.09%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Adherex Technologies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher valuation & earnings, ICCC or FENC? Adherex Technologies has higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuCell$26.49M2.10-$2.16M-$0.07-87.71Adherex Technologies$47.54M4.72-$440K-$0.51-15.82 Does the media prefer ICCC or FENC? In the previous week, Adherex Technologies had 5 more articles in the media than ImmuCell. MarketBeat recorded 6 mentions for Adherex Technologies and 1 mentions for ImmuCell. Adherex Technologies' average media sentiment score of 0.39 beat ImmuCell's score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of ICCC or FENC? 13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 6.6% of ImmuCell shares are owned by insiders. Comparatively, 11.8% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAdherex Technologies beats ImmuCell on 14 of the 17 factors compared between the two stocks. Get ImmuCell News Delivered to You Automatically Sign up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ICCC vs. The Competition Export to ExcelMetricImmuCellMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.85M$10.44B$5.48B$9.57BDividend YieldN/A2.03%4.00%4.18%P/E Ratio-87.7019.2529.8825.14Price / Sales2.1023.33440.45103.02Price / Cash96.1121.8135.9458.58Price / Book1.992.848.105.59Net Income-$2.16M$211.77M$3.26B$265.48M7 Day Performance2.33%1.54%0.65%1.22%1 Month Performance-7.39%2.31%2.44%0.39%1 Year Performance62.86%-11.48%27.59%23.47% ImmuCell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ICCCImmuCell0.0634 of 5 stars$6.14-0.6%N/A+63.7%$55.85M$26.49M-87.7070News CoverageUpcoming EarningsFENCAdherex Technologies2.3385 of 5 stars$8.66+0.3%$13.00+50.1%+40.1%$238.19M$47.54M-16.9810Upcoming EarningsBTMDbiote2.7996 of 5 stars$4.37+1.2%$8.00+83.1%-58.1%$236.35M$197.19M7.16194News CoverageEarnings ReportAnalyst ForecastGap DownPRQRProQR Therapeutics1.4391 of 5 stars$2.24+0.4%$8.00+257.1%+12.0%$234.63M$18.97M-6.40180News CoveragePositive NewsCGCCanopy Growth0.5611 of 5 stars$1.09-4.4%N/A-83.6%$233.87M$269.00M-0.273,150LRMRLarimar Therapeutics2.8736 of 5 stars$3.64-6.2%$18.50+408.2%-48.8%$233.06MN/A-2.4430Positive NewsInsider TradeGap UpDSGNDesign Therapeutics0.2153 of 5 stars$4.04+0.5%$4.00-1.0%-2.7%$228.21MN/A-4.0840News CoverageEarnings ReportLIMNLiminatus PharmaN/A$8.08-7.2%N/AN/A$226.59MN/A0.00N/AVTYXVentyx Biosciences2.5719 of 5 stars$3.04-4.4%$10.00+228.9%+20.4%$226.29MN/A-1.7430News CoveragePositive NewsEarnings ReportUpcoming EarningsRAPTRapt Therapeutics4.1463 of 5 stars$12.67-4.8%$21.67+71.0%-46.8%$220.09MN/A-0.6680Earnings ReportMDWDMediWound2.166 of 5 stars$19.93-2.0%$32.25+61.8%+14.9%$219.72M$20.22M-9.5480Positive NewsUpcoming Earnings Related Companies and Tools Related Companies FENC Alternatives BTMD Alternatives PRQR Alternatives CGC Alternatives LRMR Alternatives DSGN Alternatives LIMN Alternatives VTYX Alternatives RAPT Alternatives MDWD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ICCC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuCell Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuCell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ICCC Stock Alerts